Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GHSR | Q92847 | 12/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24528738 | 0.92 | GHSR (0.42) | KMT2AGHSRLMNAMAPK1HTT | |
| SCHEMBL30828046 | 0.92 | GHSR (0.42) | KMT2AGHSRLMNAMAPK1HTT | |
| SCHEMBL24528888 | 0.86 | NR1H2 (0.44) | KMT2AGHSRNR1H2LMNAMAPK1 | |
| SCHEMBL24528893 | 0.85 | HRH3 (0.44) | KMT2AGHSRNR1H2LMNAMAPK1 | |
| SCHEMBL5776482 | 0.81 | NR1H2 (0.44) | KMT2AGHSRNR1H2LMNAMAPK1 | |
| SCHEMBL24528894 | 0.81 | NR1H2 (0.40) | KMT2AGHSRNR1H2LMNAMAPK1 | |
| SCHEMBL31680225 | 0.80 | GHSR (0.42) | KMT2AGHSRLMNAMAPK1HTT | |
| SCHEMBL19643138 | 0.80 | GHSR (0.42) | KMT2AGHSRLMNAMAPK1HTT | |
| SCHEMBL24529019 | 0.79 | GHSR (0.36) | GHSR | |
| SCHEMBL24529088 | 0.78 | HRH3 (0.41) | KMT2AGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115711-A1 | Novel Bifunctional Molecules For Targeted Protein Degradation | PSMG3, MYCBP2, PSME2 | KMT2A 3634/4885GHSR 4309/4885NR1H2 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.